Four IPOs are expected to raise $2 billion before the Fourth of July, led by commercial data analytics provider Dun & Bradstreet (DNB). Dun & Bradstreet (DNB) plans to raise $1.3 billion at a market cap of $8 billion. The...read more
Calliditas Therapeutics, a Swedish biotech developing therapies for orphan kidney and liver diseases, raised $90 million in an upsized IPO by offering 4.6 million ADS equivalents at $19.50 per ADS. It originally planned to raise $75 million by offering 3.8...read more
IPOs are once again gaining steam and the calendar is flush with deals. With the IPO Index near all-time highs (tracked by NYSE: IPO), there are now eight offerings slated to price, making it...read more
Calliditas Therapeutics, a Swedish biotech developing novel therapies for inflammatory kidney disease, announced terms for its IPO on Monday. The Stockholm, Sweden-based company plans to raise $75 million by offering 3.8 million ADSs at $19.77, the...read more
US IPO Week Ahead: Dun & Bradstreet returns to public market in shortened 4 IPO week
Four IPOs are expected to raise $2 billion before the Fourth of July, led by commercial data analytics provider Dun & Bradstreet (DNB). Dun & Bradstreet (DNB) plans to raise $1.3 billion at a market cap of $8 billion. The...read more
Calliditas Therapeutics prices upsized US IPO at $19.50 per ADS, at slight discount to Stockholm listing
Calliditas Therapeutics, a Swedish biotech developing therapies for orphan kidney and liver diseases, raised $90 million in an upsized IPO by offering 4.6 million ADS equivalents at $19.50 per ADS. It originally planned to raise $75 million by offering 3.8...read more
This is the IPO market’s busiest week of the year with 8 deals on the calendar
IPOs are once again gaining steam and the calendar is flush with deals. With the IPO Index near all-time highs (tracked by NYSE: IPO), there are now eight offerings slated to price, making it...read more
Swedish kidney disease biotech Calliditas Therapeutics sets terms for $75 million US IPO
Calliditas Therapeutics, a Swedish biotech developing novel therapies for inflammatory kidney disease, announced terms for its IPO on Monday. The Stockholm, Sweden-based company plans to raise $75 million by offering 3.8 million ADSs at $19.77, the...read more